Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Type of study
Language
Affiliation country
Publication year range
1.
J Med Food ; 17(9): 972-8, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25115132

ABSTRACT

The purpose of this study was to examine the antiobesity effects of Monascus pilosus-fermented black soybean (F-BS) in C57BL/6 mice with high-fat diet (HFD)-induced obesity. F-BS (oral, 0.5 and 1.0 g/kg per body weight, twice per day) ameliorated obesity by reducing body and liver weight increases, and regulating blood glucose and cholesterol levels in C57BL/6 mice fed a control or HFD with oral administration of F-BS for 12 weeks. F-BS suppressed the growth of epididymal, retroperitoneal, and perirenal fat pads by preventing increases in the adipocyte size. Moreover, the levels of blood glucose, total cholesterol, and leptin were significantly lowered by F-BS administration in a dose-dependent manner. These results indicated that F-BS is a beneficial food supplement for preventing obesity, controlling blood glucose, and lowering cholesterol. Future research strategies should address the mechanisms that selectively regulate obesity, including hyperglycemia and hypercholesterolemia.


Subject(s)
Adipose Tissue/drug effects , Diet, High-Fat/adverse effects , Fermentation , Glycine max , Monascus/metabolism , Obesity/diet therapy , Plant Extracts/therapeutic use , Adipocytes/drug effects , Adipose Tissue/cytology , Animals , Anti-Obesity Agents , Blood Glucose/metabolism , Cholesterol/blood , Dose-Response Relationship, Drug , Hypoglycemic Agents/pharmacology , Hypoglycemic Agents/therapeutic use , Hypolipidemic Agents/pharmacology , Hypolipidemic Agents/therapeutic use , Leptin/blood , Liver/drug effects , Male , Mice, Inbred C57BL , Obesity/etiology , Plant Extracts/pharmacology , Soy Foods , Weight Gain/drug effects
2.
Bioorg Med Chem Lett ; 18(24): 6458-61, 2008 Dec 15.
Article in English | MEDLINE | ID: mdl-18993061

ABSTRACT

An analogue of an antitumor bicyclic hexapeptide RA-VII was prepared, in which the Ala-2 and Tyr-3 residues of RA-VII were replaced by a cycloisodityrosine unit. In the crystalline state, the peptide backbone structures and the side-chain conformations at Tyr-3, Tyr-5, and Tyr-6 of this analogue and of RA-II were very similar. This analogue, however, showed much weaker cytotoxicity against P-388 leukemia cells than parent RA-VII.


Subject(s)
Peptides, Cyclic/chemical synthesis , Peptides, Cyclic/pharmacology , Chemistry, Pharmaceutical/methods , Crystallography, X-Ray/methods , Drug Design , Drug Screening Assays, Antitumor/methods , Magnetic Resonance Spectroscopy , Models, Chemical , Molecular Conformation , Peptides/chemistry , Peptides, Cyclic/chemistry , Plant Extracts/metabolism , Rubia/metabolism , Tyrosine/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL